JPRN-UMIN000004297已完成未知
Clinical phase II study of cisplatin plus gemcitabine followed by switch maintenance docetaxel for advanced squamous-cell lung cancer - Clinical phase II study of cisplatin plus gemcitabine followed by switch maintenance docetaxel for advanced squamous-cell lung cancer
Okayama Lung Cancer Study Group0 个研究点目标入组 40 人开始时间: 2010年9月29日最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •pts with active co-morbidities including severe conditions of heart diseases, gastric ulcers, infections, uncontrollable diabetes, psychlogicai diseases, hypertension, active interstitial and hearing loss. pts with active other cancers pts with massive pleural and cardiac effusion and ascites that need to be immediately treated pts with symptomatic brain metastases
研究者
相似试验
进行中（未招募）
2 期
Phase II Study of Cisplatin, Gemcitabine, and Necitumumab in Patients with Unresectable, Advanced or Recurrent Squamous Cell Carcinoma of the Lung after Combination of Immunotherapy and Chemotherapy.Squamous cell carcinomaon-small-cell lung cancerJPRN-jRCTs051200138Yoshioka Hiroshige45
进行中（未招募）
1 期
Randomized phase 2 study of gemcitabine/cisplatin with or without SAR240550(BSI-201), a PARP1 inhibitor, in patients with stage IV non-small cell lung canceron-small cell lung cancer stage IV.MedDRA version: 12.1Level: LLTClassification code 10029522Term: Non-small cell lung cancer stage IVEUCTR2009-017270-21-FRsanofi-aventis recherche & développement105
进行中（未招募）
不适用
Randomized phase 2 study of gemcitabine/cisplatin with or without SAR240550(BSI-201), a PARP1 inhibitor, in patients with stage IV non-small cell lung canceron-small cell lung cancer stage IV.MedDRA version: 12.1Level: LLTClassification code 10029522Term: Non-small cell lung cancer stage IVEUCTR2009-017270-21-DEsanofi-aventis recherche & développement
进行中（未招募）
不适用
Randomized phase 2 study of gemcitabine/cisplatin with or without SAR240550 (BSI-201), a PARP1 inhibitor, in patients with stage IV non-small cell lung canceron-small cell lung cancer stage IVMedDRA version: 14.0Level: PTClassification code 10029522Term: Non-small cell lung cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2009-017270-21-ITsanofi-aventis recherche & de'veloppement105
进行中（未招募）
1 期
Randomized phase 2 study of gemcitabine/cisplatin with or without SAR240550 (BSI-201), a PARP1 inhibitor, in patients with stage IV non-small cell lung canceron-small cell lung cancer stage IV.MedDRA version: 12.1 Level: LLT Classification code 10029522 Term: Non-small cell lung cancer stage IVEUCTR2009-017270-21-GBsanofi-aventis recherche & développement105